A recent study demonstrated that the targeted inhibition of STAT3 in tumor-associated myeloid cells increases the efficacy of radiotherapy against head and neck squamous cell carcinoma by reducing M2 macrophages and triggering T cell-mediated anti-tumor immune responses [59]. The gene discussed is STAT3; the disease is neoplasm.